The American Society of Peritoneal Surface Malignancies Multi-Institution evaluation of 1,051 advanced ovarian cancer patients undergoing cytoreductive surgery and HIPEC

An introduction of the peritoneal surface disease severity score

Richard Sleightholm, Jason M Foster, Lynette M Smith, Wim Ceelen, Marcello Deraco, Yusuf Yildirim, Edward Levine, Cristobal Muñoz-Casares, Olivier Glehen, Asish Patel, Jesus Esquivel

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Background: Standard treatment for ovarian epithelial cancer (OEC) consists of cytoreductive surgery (CRS) and a platinum–taxane chemotherapy combination. There is increasing interest in evaluating hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with stage IIIC/IV disease. The peritoneal surface disease severity score (PSDSS) was introduced as a basis to improve patient selection for this therapy in OEC. Methods: The charts of 1,051 patients with advanced OEC who underwent CRS/HIPEC were retrospectively evaluated using the following preoperatively obtained criteria: symptoms, peritoneal dissemination, and tumor histology. Overall survival was analyzed according to PSDSS as well as the timings and agents used during CRS/HIPEC. Results: Median survival for all 1,051 patients was 73.4 months. PSDSS information was available for 553 patients. Survival correlated negatively with PSDSS (P < 0.001). Furthermore, combining PSDSS scores into I/II and III/IV described two distinct patient populations with vastly different outcomes, 100 versus 55 months, respectively (P < 0.001). Multivariate analysis failed to describe any differences between timings of HIPEC or chemotherapy agents used. Conclusion: PSDSS was capable of identifying a better surviving patient population in advanced-stage OEC. While randomized trials to evaluate the benefit of HIPEC are needed, the PSDSS may be a useful tool for selecting and stratifying OEC patients in clinical trials. J. Surg. Oncol. 2016;114:779–784.

Original languageEnglish (US)
Pages (from-to)779-784
Number of pages6
JournalJournal of Surgical Oncology
Volume114
Issue number7
DOIs
StatePublished - Dec 1 2016

Fingerprint

Peritoneal Diseases
Ovarian Neoplasms
Drug Therapy
Neoplasms
Survival
Combination Drug Therapy
Patient Selection
Population
Histology
Multivariate Analysis
Ovarian epithelial cancer
Clinical Trials

Keywords

  • CRS
  • HIPEC
  • OEC
  • ovarian epithelial cancer
  • PSDSS

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

The American Society of Peritoneal Surface Malignancies Multi-Institution evaluation of 1,051 advanced ovarian cancer patients undergoing cytoreductive surgery and HIPEC : An introduction of the peritoneal surface disease severity score. / Sleightholm, Richard; Foster, Jason M; Smith, Lynette M; Ceelen, Wim; Deraco, Marcello; Yildirim, Yusuf; Levine, Edward; Muñoz-Casares, Cristobal; Glehen, Olivier; Patel, Asish; Esquivel, Jesus.

In: Journal of Surgical Oncology, Vol. 114, No. 7, 01.12.2016, p. 779-784.

Research output: Contribution to journalArticle

Sleightholm, Richard ; Foster, Jason M ; Smith, Lynette M ; Ceelen, Wim ; Deraco, Marcello ; Yildirim, Yusuf ; Levine, Edward ; Muñoz-Casares, Cristobal ; Glehen, Olivier ; Patel, Asish ; Esquivel, Jesus. / The American Society of Peritoneal Surface Malignancies Multi-Institution evaluation of 1,051 advanced ovarian cancer patients undergoing cytoreductive surgery and HIPEC : An introduction of the peritoneal surface disease severity score. In: Journal of Surgical Oncology. 2016 ; Vol. 114, No. 7. pp. 779-784.
@article{4ab4177e6b644c448a7e4edd06e9c2a5,
title = "The American Society of Peritoneal Surface Malignancies Multi-Institution evaluation of 1,051 advanced ovarian cancer patients undergoing cytoreductive surgery and HIPEC: An introduction of the peritoneal surface disease severity score",
abstract = "Background: Standard treatment for ovarian epithelial cancer (OEC) consists of cytoreductive surgery (CRS) and a platinum–taxane chemotherapy combination. There is increasing interest in evaluating hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with stage IIIC/IV disease. The peritoneal surface disease severity score (PSDSS) was introduced as a basis to improve patient selection for this therapy in OEC. Methods: The charts of 1,051 patients with advanced OEC who underwent CRS/HIPEC were retrospectively evaluated using the following preoperatively obtained criteria: symptoms, peritoneal dissemination, and tumor histology. Overall survival was analyzed according to PSDSS as well as the timings and agents used during CRS/HIPEC. Results: Median survival for all 1,051 patients was 73.4 months. PSDSS information was available for 553 patients. Survival correlated negatively with PSDSS (P < 0.001). Furthermore, combining PSDSS scores into I/II and III/IV described two distinct patient populations with vastly different outcomes, 100 versus 55 months, respectively (P < 0.001). Multivariate analysis failed to describe any differences between timings of HIPEC or chemotherapy agents used. Conclusion: PSDSS was capable of identifying a better surviving patient population in advanced-stage OEC. While randomized trials to evaluate the benefit of HIPEC are needed, the PSDSS may be a useful tool for selecting and stratifying OEC patients in clinical trials. J. Surg. Oncol. 2016;114:779–784.",
keywords = "CRS, HIPEC, OEC, ovarian epithelial cancer, PSDSS",
author = "Richard Sleightholm and Foster, {Jason M} and Smith, {Lynette M} and Wim Ceelen and Marcello Deraco and Yusuf Yildirim and Edward Levine and Cristobal Mu{\~n}oz-Casares and Olivier Glehen and Asish Patel and Jesus Esquivel",
year = "2016",
month = "12",
day = "1",
doi = "10.1002/jso.24406",
language = "English (US)",
volume = "114",
pages = "779--784",
journal = "Journal of Surgical Oncology",
issn = "0022-4790",
publisher = "Wiley-Liss Inc.",
number = "7",

}

TY - JOUR

T1 - The American Society of Peritoneal Surface Malignancies Multi-Institution evaluation of 1,051 advanced ovarian cancer patients undergoing cytoreductive surgery and HIPEC

T2 - An introduction of the peritoneal surface disease severity score

AU - Sleightholm, Richard

AU - Foster, Jason M

AU - Smith, Lynette M

AU - Ceelen, Wim

AU - Deraco, Marcello

AU - Yildirim, Yusuf

AU - Levine, Edward

AU - Muñoz-Casares, Cristobal

AU - Glehen, Olivier

AU - Patel, Asish

AU - Esquivel, Jesus

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Background: Standard treatment for ovarian epithelial cancer (OEC) consists of cytoreductive surgery (CRS) and a platinum–taxane chemotherapy combination. There is increasing interest in evaluating hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with stage IIIC/IV disease. The peritoneal surface disease severity score (PSDSS) was introduced as a basis to improve patient selection for this therapy in OEC. Methods: The charts of 1,051 patients with advanced OEC who underwent CRS/HIPEC were retrospectively evaluated using the following preoperatively obtained criteria: symptoms, peritoneal dissemination, and tumor histology. Overall survival was analyzed according to PSDSS as well as the timings and agents used during CRS/HIPEC. Results: Median survival for all 1,051 patients was 73.4 months. PSDSS information was available for 553 patients. Survival correlated negatively with PSDSS (P < 0.001). Furthermore, combining PSDSS scores into I/II and III/IV described two distinct patient populations with vastly different outcomes, 100 versus 55 months, respectively (P < 0.001). Multivariate analysis failed to describe any differences between timings of HIPEC or chemotherapy agents used. Conclusion: PSDSS was capable of identifying a better surviving patient population in advanced-stage OEC. While randomized trials to evaluate the benefit of HIPEC are needed, the PSDSS may be a useful tool for selecting and stratifying OEC patients in clinical trials. J. Surg. Oncol. 2016;114:779–784.

AB - Background: Standard treatment for ovarian epithelial cancer (OEC) consists of cytoreductive surgery (CRS) and a platinum–taxane chemotherapy combination. There is increasing interest in evaluating hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with stage IIIC/IV disease. The peritoneal surface disease severity score (PSDSS) was introduced as a basis to improve patient selection for this therapy in OEC. Methods: The charts of 1,051 patients with advanced OEC who underwent CRS/HIPEC were retrospectively evaluated using the following preoperatively obtained criteria: symptoms, peritoneal dissemination, and tumor histology. Overall survival was analyzed according to PSDSS as well as the timings and agents used during CRS/HIPEC. Results: Median survival for all 1,051 patients was 73.4 months. PSDSS information was available for 553 patients. Survival correlated negatively with PSDSS (P < 0.001). Furthermore, combining PSDSS scores into I/II and III/IV described two distinct patient populations with vastly different outcomes, 100 versus 55 months, respectively (P < 0.001). Multivariate analysis failed to describe any differences between timings of HIPEC or chemotherapy agents used. Conclusion: PSDSS was capable of identifying a better surviving patient population in advanced-stage OEC. While randomized trials to evaluate the benefit of HIPEC are needed, the PSDSS may be a useful tool for selecting and stratifying OEC patients in clinical trials. J. Surg. Oncol. 2016;114:779–784.

KW - CRS

KW - HIPEC

KW - OEC

KW - ovarian epithelial cancer

KW - PSDSS

UR - http://www.scopus.com/inward/record.url?scp=84992454669&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992454669&partnerID=8YFLogxK

U2 - 10.1002/jso.24406

DO - 10.1002/jso.24406

M3 - Article

VL - 114

SP - 779

EP - 784

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

SN - 0022-4790

IS - 7

ER -